Provides risk management solutions to businesses and governments. Offers scientific, technical, and medical information to researchers and healthcare professionals. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The gap is $9.7B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 39% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 22% — still a thick cushion, though costs have been eating into it lately.
It pays out $0.91 per share each year — regular cash for whoever holds the stock.
The stock trades 23% above the average analyst price target.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 47/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, RELX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: RELX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.